Weekly Rundown: Key Catalysts for Small-Cap Stocks (January 12-16)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch this week. As we head into mid-January, attention turns to one of the most impactful events on the healthcare calendar — the J.P. Morgan 44th Annual Healthcare Conference, taking place January 12–15, 2026, in San Francisco, CA. Widely regarded as the industry's most influential investment symposium, the conference draws over 8,000 participants — including C-suite executives, institutional investors, analysts, and policymakers — across biotech, pharma, medtech, and digital health. With a packed agenda of corporate presentations, fireside chats, and one-on-one meetings, the event sets the tone for healthcare dealmaking, innovation, and investor sentiment heading into Q1. Here’s your weekly preview

44th Annual J.P. Morgan Healthcare Conference January 12–15, 2026 | San Francisco, CA

Regarded as the most influential healthcare investment event of the year, JPM 2026 brings together over 8,000 healthcare leaders, institutional investors, and policymakers. For small-cap companies, this is a key platform to share milestones, data, pipeline progress, and strategic roadmaps for 2026.

BFLY will present on Thursday, January 15 at 9:00 AM PT. CEO Joseph DeVivo and senior leadership will also host investor meetings throughout the week.

LRMR, CLLS, ACHV, BEAT, AVIR, and SRTS will conduct 1x1 meetings during the event.

MOLN CEO Patrick Amstutz presents on January 15 at 10:30 AM PT at the Westin St. Francis.

IVA CEO Andrew Obenshain presents on January 15 at 9:00 AM PT and hosts meetings on January 14.

BMEA interim CEO Mick Hitchcock presents January 14 at 5:15 PM PT, with meetings throughout the week.

CHRS presents January 13 at 10:30 AM PT; ERAS presents January 13 at 1:30 PM PT.

RXRX CEO Najat Khan presents January 13 at 10:30 AM PT.

SANA presents January 14 at 9:45 AM PT; PRME presents at 9:00 AM PT that same day.

CMPX, PROK, OM, ESPR, RCKT, CATX, ABSI, ABCL, ALXO, ADCT, RPID, SABS, TALK, CLOV, IRD, LXRX, OCGN, PGEN, PACB, INNV, and PMI will also present or meet with investors during the conference.

DRTS will present on January 15 at 11:15 AM PT and meet with institutional investors.

LGVN, CLRB, IMUX, ATAI, STKL, and ENVB are also attending related JPM Week events.

Biotech Showcase January 12–14, 2026 | San Francisco, CA

Running in parallel to JPM, Biotech Showcase offers smaller-cap companies a chance to present to institutional investors.

MDCX presents on January 13 at 10:00 AM PT.

AZTR, AKTX, KLTO, ICU, and SNTI will participate in meetings, panels, or presentations.

ENVB, GANX, and CLRB will also participate and conduct one-on-one investor meetings during the event.

Sachs Neuroscience Innovation Forum January 11, 2026 | San Francisco, CA

This one-day forum kicks off JPM Week, highlighting innovation across neurology and mental health.

GANX and ENVB will participate in panels and investor meetings throughout the event.

28th Annual Needham Growth Conference January 13–16, 2026 | New York City & Virtual

Needham’s premier investor event spans healthcare, technology, and industrial growth names.

CURI will participate in a fireside chat at 3:45 PM ET on January 14.

BITF, REAX, SQNS, CRNT, GDRX, STEX, SVCO, DH, PDYN, STGW, TBLA, NRDY, LWLG, SES, and SRFM are among participants with scheduled meetings or presentations.

HLYN will present on January 16 at 9:30 AM ET and hold one-on-one meetings with investors.

RCKT, DH, and SVCO also have fireside chats scheduled for January 14.

28th Annual ICR Conference January 12–14, 2026 | Orlando, FL

One of the top conferences for consumer and lifestyle brands, ICR brings management teams together with the investment community to discuss brand positioning, M&A, and outlooks for the year ahead.

SNAL, CRWS, ZVIA, HFFG, VNCE, SST, STKL, STKE, HITI and BRCC are scheduled to present or meet with investors.

Other Notable Events and Announcements

• TIVC will host a webcast on January 12 at 4:30 PM ET to discuss its acquisition of CDMO assets and the strategic impact on its drug development pipeline.

• GANX will attend three JPM Week events: Sachs Neuroscience Forum (Jan 11), Biotech Showcase (Jan 12–14), and LifeSci Advisors Corporate Access (Jan 14).

• NAUT will host a webinar titled “Advancing next-generation proteomics with single-molecule Iterative Mapping” on January 14 at 9:00 AM PT.

• FBIO and its majority-owned subsidiary Cyprium Therapeutics announced that the U.S. FDA has accepted the resubmission of the New Drug Application for CUTX-101 (copper histidinate), a treatment for Menkes disease in pediatric patients. The resubmission was accepted as a Class 1 review, establishing a new PDUFA target action date of January 14, 2026.

• UPXI will attend the AlphaNorth Capital Event from January 16–18, 2026 at the Grand Hyatt Baha Mar in Nassau, Bahamas.

• NWTG will also attend the AlphaNorth Capital Event from January 16–18, 2026 at the Grand Hyatt Baha Mar in Nassau, Bahamas. CEO Greg Campbell will participate in investor meetings.

• AUUD extended its LOI exclusivity period for a merger with Thramann Holdings through January 16.

• RPTX will hold a special shareholder meeting on January 16 to vote on its acquisition by Xeno.

• ORMP approved a $0.25 per share dividend, with an ex-date of January 16 and payment scheduled for January 26.

• NRO declared a distribution of $0.0312 per share, payable January 30 to shareholders of record as of January 15.

• XRTX aims to close its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Program by January 13.

• OFAL announced the successful completion of application testing for its next-generation intelligent building platform QikBIM, along with continued smooth progress in testing its Real-World Asset (RWA) platform. Following comprehensive validation of both architectural and structural functions, QikBIM is scheduled to officially enter commercial operation on January 15, 2026. Upon launch, it is expected to become a core technology pillar of OFAL’s commercialization strategy and long-term revenue growth.

• NRXS will present at the Lytham Partners Healthcare Investor Summit on Thursday, January 15, 2026 at 9:30 a.m. ET.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.